Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I)
dc.contributor.author | Pitt, Bertram | en_US |
dc.contributor.author | Ellis, Stephen G. | en_US |
dc.contributor.author | Mancini, G. B. John | en_US |
dc.contributor.author | Rosman, Howard S. | en_US |
dc.contributor.author | McGovern, Mark E. | en_US |
dc.contributor.author | The PLAC I Investigators, | en_US |
dc.date.accessioned | 2006-04-10T15:40:49Z | |
dc.date.available | 2006-04-10T15:40:49Z | |
dc.date.issued | 1993-07-01 | en_US |
dc.identifier.citation | Pitt, Bertram, Ellis, Stephen G., Mancini, G. B. John, Rosman, Howard S., McGovern, Mark E., The PLAC I Investigators, (1993/07/01)."Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I)." The American Journal of Cardiology 72(1): 31-35. <http://hdl.handle.net/2027.42/30692> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6T10-4C7099B-171/2/715939d1ae3ed7d9ae5b7a187d59312d | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/30692 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8517425&dopt=citation | en_US |
dc.description.abstract | The present study was designed to test the effect of pravastatin, a new, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on the progression of coronary artery disease in patients with moderate hypercholesterolemia. Angiographic entry criteria included the presence of >=1 stenosis >=50% in a major epicardial coronary artery, and certification of film quality through the core angiography laboratory. Patients qualified for randomization if after diet stabilization their low density lipoprotein cholesterol concentrations were >=130 and < 190 mg/dl, and triglycerides were <= 350 mg/dl. Pravastatin (40 mg) or placebo is administered once daily at bedtime. Arteriography will be repeated at the end of 3 years of treatment. The primary end point of the study is the change in absolute mean coronary artery diameter. During a 30-month recruitment period, 44,145 patients were screened, and 408 were randomized. The most frequent reason for excluding patients during the screening and dietary lead-in periods was a low serum cholesterol level. A large proportion of patients with documented coronary artery disease have cholesterol concentrations that are considered to be normal or only modestly increased. Adherence to strict standards of quality control for digital analysis of angiograms ensures that baseline angiograms can be interpreted at the end of 3-year follow-up. | en_US |
dc.format.extent | 581416 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I) | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Hospital, Ann Arbor, Michigan, USA; Cleveland Clinic Foundation, Cleveland, Ohio, USA; University Hospital, University of British Columbia, Vancouver, British Columbia, Canada; Henry Ford Hospital, Detroit, Michigan, USA; Bristol-Myers Squibb, Pharmaceutical Research Institute, Princeton, New Jersey, USA. | en_US |
dc.contributor.affiliationum | Cleveland Clinic Foundation, Cleveland, Ohio, USA; University Hospital, University of British Columbia, Vancouver, British Columbia, Canada; Henry Ford Hospital, Detroit, Michigan, USA; Bristol-Myers Squibb, Pharmaceutical Research Institute, Princeton, New Jersey, USA; University of Michigan Hospital, Ann Arbor, Michigan, USA. | en_US |
dc.contributor.affiliationum | Cleveland Clinic Foundation, Cleveland, Ohio, USA; University Hospital, University of British Columbia, Vancouver, British Columbia, Canada; Henry Ford Hospital, Detroit, Michigan, USA; Bristol-Myers Squibb, Pharmaceutical Research Institute, Princeton, New Jersey, USA; University of Michigan Hospital, Ann Arbor, Michigan, USA. | en_US |
dc.contributor.affiliationum | Cleveland Clinic Foundation, Cleveland, Ohio, USA; University Hospital, University of British Columbia, Vancouver, British Columbia, Canada; Henry Ford Hospital, Detroit, Michigan, USA; Bristol-Myers Squibb, Pharmaceutical Research Institute, Princeton, New Jersey, USA; University of Michigan Hospital, Ann Arbor, Michigan, USA. | en_US |
dc.contributor.affiliationum | Cleveland Clinic Foundation, Cleveland, Ohio, USA; University Hospital, University of British Columbia, Vancouver, British Columbia, Canada; Henry Ford Hospital, Detroit, Michigan, USA; Bristol-Myers Squibb, Pharmaceutical Research Institute, Princeton, New Jersey, USA; University of Michigan Hospital, Ann Arbor, Michigan, USA. | en_US |
dc.contributor.affiliationum | Cleveland Clinic Foundation, Cleveland, Ohio, USA; University Hospital, University of British Columbia, Vancouver, British Columbia, Canada; Henry Ford Hospital, Detroit, Michigan, USA; Bristol-Myers Squibb, Pharmaceutical Research Institute, Princeton, New Jersey, USA; University of Michigan Hospital, Ann Arbor, Michigan, USA. | en_US |
dc.identifier.pmid | 8517425 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/30692/1/0000337.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0002-9149(93)90214-W | en_US |
dc.identifier.source | The American Journal of Cardiology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.